EPZM News and Press, Epizyme Inc. From 03/19/20

For those with cash on the sidelines, the precipitous market drop means there are currently some promising companies at attractive prices. Let's delve into three exciting cancer drug developers worth strong consideration. One has successfully commercialized its cancer drug and is expanding its ...

Osmotica Pharmaceuticals (NASDAQ: OSMT ) initiated with Buy rating and $8 (74% upside) price target at SunTrust. More news on: Osmotica Pharmaceuticals plc, Epizyme, Inc., Baxter International Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Institutional investors rushed to acquire shares of cancer drug developer Epizyme (NASDAQ: EPZM) in advance of a catalyst-rich 2020. Those who acted were not disappointed. In January, the Food and Drug Administration (FDA) granted accelerated approval for the company's targeted cancer drug, ...

Image source: The Motley Fool. Epizyme Inc   (NASDAQ: EPZM) Q4 2019 Earnings Call Feb 24, 2020 , 8:30 a.m. ET Operator Continue reading

Epizyme, Inc. (EPZM) Q4 2019 Results Earnings Conference Call February 24, 2020, 08:30 AM ET Company Participants Alicia Davis - IR Rob Bazemore - Chief Executive Officer Shefali Agarwal - Chief Medical Officer Matt Ross - Chief Strategy and Business Officer Paolo Tombesi - C...

Shares of Epizyme (NASDAQ: EPZM) fell as much as 17.4% today after the company released fourth-quarter and full-year 2019 operating results. There wasn't much for investors to pick apart. The company is in the early stages of transitioning to commercial operations, which means it doesn't hav...

Epizyme ( EPZM ) Q4 results : More news on: Epizyme, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Epizyme (NASDAQ: EPZM ): Q4 GAAP EPS of -$0.59 misses by $0.08 . Revenue of $4.29M (-55.8% Y/Y) beats by $1.21M . Press Release More news on: Epizyme, Inc., Earnings news and commentary, Healthcare stocks news,

TAZVERIK™ (tazemetostat) Commercial Launch Underway for Epithelioid Sarcoma TAZVERIK sNDA for Follicular Lymphoma Accepted for Filing by FDA with Priority Review; PDUFA Target Action Date of June 18, 2020 Expanding Future TAZVERIK Value through Clinical Development into Ne...

The FDA Accepts Epizyme Marketing Application Epizyme ( EPZM ) reported that the FDA has accepted its marketing application regarding Tazverik. The treatment is being developed for managing patients with relapsed or refractory lymphoma who have received at least two prior lines of systemi...